Price movement over the last 24 hours
AdaptHealth Corp vs Las Vegas Sands Corp. — how do they compare? AdaptHealth Corp trades at $10.02 (market cap $1.38B), while Las Vegas Sands Corp. trades at $46.26 (market cap $30.52B). The key difference: Las Vegas Sands Corp. is far larger — about 22.1× AdaptHealth Corp's market cap, and Las Vegas Sands Corp. pays a 2.39% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | LVS | |
|---|---|---|
Market Cap | $1.38B | $30.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $13.38 | $69.49 |
52-Week Low | $8.68 | $46.06 |
Enterprise Value | $3.33B | $42.92B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
LVS trades at $46.06, down 1.98% on the day, amid a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations, and maintains robust profitability with a net income margin of 13.41%. Recent news highlights ESG achievements and Macao's economic diversification efforts. Cash flow trends show positive net cash flow in 2025 after previous years of outflows.
The outlook for LVS is supported by solid fundamentals and analyst optimism, with a consensus price target of $66.38 implying significant upside. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and exposure to Macao's regulatory environment. Institutional sentiment remains positive, with no sell ratings among 49 analysts.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →